Assessing Quality of Inhaled Products And Links to Efficacy and Safety
|
|
- Ashley Carr
- 5 years ago
- Views:
Transcription
1 Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, Outline of the Presentation FDA proposed updates to the 1998 MDI/DPI guidance Recommended approached to developing/testing inhaled drug products Quality links to efficacy and safety. APSD DDU Challenged in QbD and Efficacy Summary 2 1
2 Current Inhaled Therapies The world market for asthma drugs > $21.94 billion by US market accounting for approximately half of the global total. 3 Orally Inhaled Products for Local Action/Systemic Delivery Propellant driven metered dose inhalers (MDIs) Dry powder inhalers (DPIs) Pre-metered singe dose unit Pre-metered multiple dose unit Drug reservoir Inhalation Sprays HandiHaler TwistHaler Diskus Nebulizers 4 2
3 1998 MDI/DPI Guidance-Comments This draft provides comprehensive recommendations for drug product characterization, manufacturing and quality control to be followed by the manufacturers of MDIs and DPIs. DCU recommendations are non parametric content uniformity tests Do not reflect fully the principles of espoused in ICH Q8, Q9, and Q10 Mass balance requirements are too tight Too prescriptive and we shouldn t be telling how to develop the drug product Working on update to the MDI/DPI Principles of Pharmaceutical Development in ICH Q8(R2) 5 Proposed Approach 6 3
4 What is QbD? Systematic approach to development Begins with predefined objectives Emphasizes product and process understanding and process control Based on sound science and quality risk management 7 Why QbD? Higher level of assurance of product quality for patient Improved product and process design and understanding Quality risk management in manufacturing Monitoring, tracking, and trending of product and process Continuous improvement Cost saving and efficiency for industry Increase efficiency of manufacturing process Minimize and eliminate potential compliance actions Provide opportunities for continual improvement Facilitate innovation More efficient regulatory oversight Streamline post approval manufacturing changes and regulatory processes 8 4
5 QbD Approach Product profile CQAs Risk assessment Design space Control strategy Continual Improvement Quality Target Product Profile (QTPP) Determine critical quality attributes (CQA) Link raw material attributes and process parameters to CQA and perform risk assessment Develop a design space Design and implement a control strategy Manage product lifecycle, including continual improvement 9 QbD Approach Product profile CQAs Risk assessment Design space Control strategy Quality target product profile Proposed dosage form Delivery system Strength (target emitted dose or target metered dose) Purity Stability Aerodynamic performance Continual Improvement 10 5
6 Product profile CQAs Risk assessment Design space Control strategy Continual Improvement QbD Approach-MDIs Critical Quality Attributes-MDIs Assay Impurities and Degradants Delivered Dose APSD Spray Pattern/Plume Geometry Leachables Excipients Foreign Particulate Matter Moisture Content Net Content Device CQAs Dose Counter 11 Linking Strength and CQAs for a MDI Strength (Target Emitted Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered Dose APSD Spray Pattern/Plume Geometry Leachables Amount of Excipient(s) Foreign Particulate Matter Moisture Content Net Content Device CQAs Dose Counter Force to fire/force to count 12 6
7 Linking Purity and CQAs for a MDI Strength (Target Emitted Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered Dose APSD Spray Pattern/Plume Geometry Leachables Amount of Excipient(s) Foreign Particulate Matter Moisture Content Net Content Device CQAs Dose Counter Force to fire/force to count 13 Linking Stability and CQAs for a MDI Strength (Target Emitted Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered Dose APSD Spray Pattern/Plume Geometry Leachables Amounts of Excipients Foreign Particulate Matter Moisture Content Net Content Device CQAs Dose Counter Force to fire/force to count 14 7
8 Linking AP and CQAs for a MDI Strength (Target Emitted Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered Dose APSD Spray Pattern/Plume Geometry Leachables Amount of Excipient(s) Foreign Particulate Matter Moisture Content Net Content Device CQAs Dose Counter Force to fire/force to count 15 QbD Approach-DPIs Product profile CQAs Risk assessment Design space Control strategy Continual Improvement Critical Quality Attributes-DPIs Assay Impurities and Degradants Delivered dose APSD Volatile/Semi volatile leachables Foreign particulate matter Moisture content Device HandiHaler Diskus TwistHaler 16 8
9 Linking Strength and CQAs for a DPI Strength (Target Metered Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered dose APSD Volatile/Semi volatile leachables Foreign particulate matter Net Content Moisture content Device 17 Linking Purity and CQAs for a DPI Strength (Target Metered Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered dose APSD Volatile/Semi volatile leachables Foreign particulate matter Net Content Moisture content Device 18 9
10 Linking Stability and CQAs for a DPI Strength (Target Metered Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered dose APSD Volatile/Semi volatile leachables Foreign particulate matter Net Content Moisture content Device 19 Linking AP and CQAs for a DPI Strength (Target Metered Dose) Purity Stability Aerodynamic Performance Assay Impurities and Degradants Delivered dose APSD Volatile/Semi volatile leachables Foreign particulate matter Net Content Moisture content Device 20 10
11 Material Attributes/Process Parameters to CQAs and Risk Product profile CQAs Risk assessment Design space Control strategy Continual improvement Risk Identification What might go wrong Historical data, theoretical analysis, informed opinions and concerns Risk Analysis Estimation of risk and linking to occurrence and severity of harm Risk Evaluation Compares identified risk to criteria 21 Tougas et al, USP presentation, Dec
12 Risk Assessment for Orally Inhaled Drug Products for Local Action Dry Powder Inhalers APSD, and, DDU or DCU Create Design Space Based on Risk Assessment Armanni et al. On-screen%20version_IPAC2008%20Poster.pdf 23 Potential for Extractables and Leachables Shaw, Arthur J.; Ball, Douglas J.; Beierschmitt, William P.; Colgan, Stephen T.; Lynch, Michael P. and Zweiben, Cindy Extractables and Leachables An Evolving Analytical Role in Drug Product Development. AAPS newsmagazine (September 2010) 24 12
13 Design Space Materials - Process - Product Materials Process Design Space Product While it is possible to have a Design space for all operations, it is not necessary as part of a QbD approach. 25 Developing Design Space for MDI Formulation vs. Droplet Size Product profile CQAs Risk assessment Design space Control strategy Continual Improvement Smith and Hickey; AAPS PharmSciTech 2003; 4 (3) 26 13
14 Product profile Design Space for a DPI Effect of spray drying parameters on APSD CQAs Risk assessment Design space Control strategy Continual Improvement Temperature Airflow Concentration 27 Device Development-1 Product profile CQAs Risk assessment Design space Control strategy Continual Improvement Steckel and Muller, Int J. Pharmaceut, 154, 19-29,
15 Device Development -2 Product profile CQAs Risk assessment Design space Control strategy Continual Improvement USP Workshop, Dec Control Strategies for APSD and DDU Product profile CQAs Risk assessment Design space Control strategy Aerodynamic Particle Size Distribution Current Approach Abbreviated Impactor Measurement (AIM) Delivered Dose Uniformity Zero Tolerance Parametric Tolerance Interval Testing Continual Improvement 30 15
16 APSD Testing The FDA 1998 guidance recommends Cascade impactors within NDAs be of the same design Control temperature and relative humidity Number of actuations based on sensitivity of method Drug substance deposited on the critical stages of the cascade impactor should be characterized Acceptance criteria proposed in terms of appropriate groupings of stages MMAD, GSD, respirable fraction, respirable dose, or fine particle mass are not considered adequate to characterize the particle size distribution of the whole dose 31 Typical APSD Specifications Stage Groups Group 1 (Adaptor- S0) Group 2 (S1-S3) Group 3 (S4-S6) Group 3 (S7-Filter) Acceptance Criteria mcg NMT 15 mcg mcg NMT 10 mcg 32 16
17 Cutoffs for Cascade Impactors at 60L/min 33 Current Trends in APSD Testing Vs. ACI AIM Pictures: Courtesy: ACI -- Ed Warner, Process Drift, PQRI FDA Workshop Dec C-FSA (Fast Screening Anderson) Copley Scientific, Inhalationmag.com, June
18 AIM Concept In 2009/2010 concepts of AIM approach was proposed by IPAC-RS for routine Quality Control. Traditional multistage cascade impaction methods for measuring APSD is labor intensive, operator inconsistency can make them subject to measurement variability. May facilitate Quality-by-Design studies and creation of the Design Space. Briefing document included papers published by Tougas et al in AAPS PharmSciTech The abbreviated impactor measurement concept, Jolyon P.Mitchell, Mark W.Nagel, and Mark Copley 35 Inhalation 2009 AIM concept reduces the 7 or 8 data points associated with the typical full resolution APSD to the 2 mass fractions assigned to fine (FPF) and coarse (CPF) particles. AIM Concept The abbreviated impactor measurement concept, Jolyon P. Mitchell, Mark W. Nagel, and 36 Mark Copley Inhalation
19 AIM Concept Tougas et al, USP, Aerodynamic Particle Size Testing of Orally Inhaled Products: Abbreviated Impactor Measurements and 37 Efficient Data Analysis (AIM/EDA) Dec 2010 IPAC-RS meeting July 2010 Contained data on 8 products (HFA MDI solution, 2 HFA MDI suspension, 2 DPIs, 3 CFC Suspensions). Publication claims that The time required is greatly reduced Improved overall precision Improve quality decisions, i.e., batch disposition. Time savings associated with AIM systems may increase samples evaluated from a batch within a fixed timeframe Reducing the number of manipulations decrease the chances of operator-related errors. Environmentally friendly by using less solvents Simpler apparatus configurations that are more amenable to automation 38 19
20 Preliminary Thoughts on AIM Statistical concerns about APSD portions (large and small particle masses) may be positively correlated to ISM. Multiple distributions can share the same LPM/SPM ratio. Uni-modal and bimodal distributions may share the same mean and variation. While it reduces variability in measurements it comes with loss of full information QC test based on only two measures considers less information than current test 39 Conclusions for AIM AIM is useful as a research tool for quick analysis! FDA recognizes that AIM will save time and hence better throughput. Will this eventually give rise to more samples being tested? If the issues highlighted by the statisticians are addressed there is scope to consider AIM and EDA as a important analytical tool. The Agency believes that better science should lead to better regulations and are open to discussion to alternative approaches to control strategies
21 DDU- Parametric Tolerance Interval Test (PTIT) PTIT is a more scientific and risk based approach to setting DDU specifications Elimination of zero tolerance criteria is appropriate in this context PTIT is an approach consistent with QbD that calls for product and process understanding Clinically relevant specification Understanding of process leads to good control of variability 41 Parametric Tolerance Interval Test (PTIT) Many applicants have proposed PTIT approaches for a number of attributes and parameters. Collaboratively within the FDA the chemists and statisticians have recommended acceptable proposals to the applicants. This avenue may be further explored not only for DDU but other attributes as well
22 Challenges to Linking APSD to Efficacy Computer mode of particle size distribution Drug on lactose particle 43 Aerodynamic Particle Size Distribution 44 Respiratory Drug Delivery 2008 Annual Meeting 22
23 APSD-Monodispersed Albuterol Study In a randomized study 12 patients with asthma inhaled 1 L aerosol of Tc labeled monodispersed albuterol 30 µg at particle sizes of 1.5, 3, and 6 µm MMAD 1.5 µm 3 µm 6 µm 1.5 µm 3 µm 6 µm Total Lung Deposition % of Total Delivered Dose Peripheral Lung Central Lung Deposition Deposition Exhaled FEV1 in ml Monodispersed aerosol may have a role in defining product profile and design space 45 Am J Respir Crit Care Med 2005; 172: APSD - Targeting Inhaled Drugs 6 µm 3 µm 1.5 µm Optimum particle size for inhaled beta-agonists appear to be 3 µm to 6 µm Optimum particle size for inhaled corticosteroids is not known 46 Respiratory Drug Delivery 2008 Annual Meeting 23
24 APSD-Monodispersed Beclomethasone Study In a randomized study 10 patients with asthma inhaled monodispersed beclomethasone at particle sizes of 1.5, 2.5, and 4.5 µm MMAD 2.5 µm 4.5 µm 1.5 µm Monodispersed aerosol may have a role in defining product profile and design space Mean plasma concentration of 17-BMP. Gastrointestinal absorption blocked by activated charcoal ingestion. 47 Br J Clin Pharmacol 2007; 64: Status of QbD for Inhaled products QbD has moved into the implementation phase of product manufacturing and control The cornerstone for QbD in inhaled products has been laid from a quality perspective FDA has seen QbD elements in applications for inhaled products. Much of science is there, and some development is needed Time is right to apply QbD approaches for efficacy and safety assessment based on product s clinical use and risk
Inhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationEPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing. Overview of AIM EDA
EPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing Overview of AIM EDA Jolyon Mitchell 1 and Mark Copley 2 1 Trudell Medical
More informationProcess Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations
Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationWhat Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation
What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects Jolyon P. Mitchell, Ph.D. Trudell Medical International London, Canada IPAC-RS Conference November 2006 1 Context of Presentation This talk
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationDevice Change Management for Inhaled Products. Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015
Device Change Management for Inhaled Products Loy Britto, Ph.D. GlaxoSmithKline ISAM Congress Munich 2015 Topics to be covered Update on ISO/TC 084/WG 15: Guidelines for development of drug products- Quality
More informationDraft Guidance on Fluticasone Propionate; Salmeterol Xinafoate. Fluticasone Propionate; Salmeterol Xinafoate. Powder/Inhalation
Reprinted from FDA s website by EAS Consulting Group, LLC Contains Nonbinding Recommendations Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate This draft guidance, once finalized, will represent
More informationLast updated: July 2011
EFFICIENT DATA ANALYSIS, ABBREVIATED IMPACTOR MEASUREMENTS, AERODYNAMIC PARTICLE SIZE DISTRIBUTIONS: PUBLICATIONS AND PRESENTATIONS BY MEMBERS OF THE IPAC-RS CASCADE IMPACTION WORKING GROUP AND EPAG 2000-2011
More informationMetered Dose Inhaler Technology
Metered Dose Inhaler Technology Edited by Tol S. Purewal and David J. W. Grant Interpharm Press, Inc. Buffalo Grove, Illinois Contents 1. INTRODUCTION 1 T. S. Purewal Definition of the Metered Dose Inhaler
More informationCOMMENTS. Submitted by The International Pharmaceutical Aerosol Consortium
COMMENTS on a draft Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Chemistry, Manufacturing, and Controls Documentation (Docket No. 99D-1454) Submitted by
More informationThe abbreviated impactor measurement concept
AS APPEARED IN Inhalation JUNE 2009 www.inhalationmag.com The abbreviated impactor measurement concept A potentially faster and more precise way to assess quality of inhaled drug products Jolyon P. Mitchell,
More informationCLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA. Steve Newman, PhD Nottingham, UK November 2006
IPAC-RS Conference 6-8 November 2006 CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA Steve Newman, PhD Nottingham, UK November 2006 IPAC-RS Conference 6-8 November 2006 1 EFFECT OF PARTICLE SIZE ON
More informationUnderstanding cascade impaction and its importance for inhaler testing
Understanding cascade impaction and its importance for inhaler testing Mark Copley, Technical Sales Manager Inhalation product development is an important area of activity for the pharmaceutical sector.
More informationImplications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products
Implications of the new CHMP Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory Affairs der Mathematisch-Naturwissenschaftlichen
More informationConsiderations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products
Considerations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products Sven Stegemann Sept 16, 2015 Institute for Process and Particle Engineering, Pharmaceutical Engineering
More informationAssessing the role of breathing simulators in OIP testing
As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can
More informationEnsuring the Quality of Some Drug-Device Combination Products - FDA Perspective
Ensuring the Quality of Some Drug-Device Combination Products - FDA Perspective PQRI Meeting, Rockville, MD - 2017 Ramesh Raghavachari, Ph.D. Chief, Branch I, DPMA I, OLDP OPQ 03/23/2017 OFFICE OF PHARMACEUTICAL
More informationEPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010
1 EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010 Overview 2 EPAG, what is it?, background, this project Regulatory
More informationGo With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific
Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.
More informationAdapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016
Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies Julie D. Suman, Ph.D. March 29, 2016 AGENDA Regulatory Approaches for Bioequivalence (BE) Compendial Testing Vs Pharmaceutical Equivalence
More informationDevice Design Similarity
Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
European Medicines Agency Inspections London, 16 February 2005 Doc Ref.: EMEA/CHMP/QWP/49313/2005 corr. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF
More informationAEROSOL THERAPY: THE PRACTICALITIES
AEROSOL THERAPY: THE PRACTICALITIES Lester I. Harrison, PhD Section Head, Clinical Pharmacokinetics, 3M Pharmaceuticals, 3M Center 270-3S-05, St. Paul, MN, USA 55144 liharrison@mmm.com Introduction: Horses,
More informationTesting Inhaled Generics
Generic Bioequivalence Testing Inhaled Generics By Mark Copley at Copley Scientific New product-specific FDA guidance and USP monographs support the development of popular inhaled products. This article
More informationISO Process and Standards Under Development. ISO Principles
Inhalation & Nasal Drugs: The Regulatory Landscape ISO Process and Standards Under Development S.C. Nichols 7 1 ISO Principles ISO standards are developed according to the following principles: Consensus
More informationPulmonary deposition of inhaled drugs
Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the last 5 years
More informationDry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationChallenges in Nonclinical Development of Inhalation Drug Products
Challenges in Nonclinical Development of Inhalation Drug Products Luqi Pei, Ph.D. Senior Pharmacologist DPARP, CDER August 6, 2015 Rockville, MD Disclaimer This speech reflects the views of the speaker
More informationREDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION
REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION In this article, Heli Chauhan, Senior Applications Chemist, and Linda (Lingzhi) Liao, Field Applications Scientist, both of Proveris
More informationSignificance of Leachables and Extractables to Pharmaceutical Quality
Significance of Leachables and Extractables to Pharmaceutical Quality Gordon Hansen, MS Vice President Analytical Development Ridgefield Boehringer Ingelheim Pharmaceuticals, Inc. Presentation Outline
More informationMetered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC
Metered Dose Inhalers (MDIs) In Vitro Measures to Confirm Patient Perceptions: HFA vs. CFC William H. Doub, Ph.D. Division of Pharmaceutical Analysis (DPA) US FDA/CDER/OPS/OTR The information presented
More informationGuidance for Industry
Guidance for Industry Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products Chemistry, Manufacturing, and Controls Documentation DRAFT GUIDANCE This document is being distributed for comment
More informationUnderstanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016
Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,
More informationINTRODUCTION. size and total nozzle area decrease with stage number. Volumetric air flow rate through
CASCADE I M P A C T I O N Optimizing Cascade Impactor Testing for Characterizing Orally Inhaled & Nasal Drug Products By: Mark Copley INTRODUCTION Cascade impaction is a core analytical technique for characterizing
More informationInternational Pharmaceutical Aerosol Consortium on Regulation and Science
International Pharmaceutical Aerosol Consortium on Regulation and Science 1500 K Street NW Washington DC 20005 Telephone +1 202 230 5607 Fax +1 202 842 8465 Email info@ipacrs.org Web www.ipacrs.org Submitted
More informationQualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations. Julie D. Suman, Ph.D. November 14, 2014
Qualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations Julie D. Suman, Ph.D. November 14, 2014 Objectives Container-Closure System Attributes Extractables Regulatory Expectations
More informationNEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS
NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of
More information2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus
2008 IPAC-RS Conference Doing the Right Thing Science, Quality and Patient Focus Patient Perspective Alpha-1 1 Foundation John W. Walsh Patient Focus Personal perspective Challenges and lessons Importance
More informationLawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration
Evolving FDA s Approach to Pharmaceutical Quality Lawrence X. Yu, Ph.D. Director (acting) Office of Pharmaceutical Science Food and Drug Administration IPAC-RS/University of Florida Orlando Inhalation
More informationDEBATING THE OPERATING CURVES FOR DDU TESTS ON MARKETED INHALERS
DEBATING THE OPERATING CURVES FOR DDU TESTS ON MARKETED INHALERS Industry s problem with the current FDA DDU requirements Presented by Bo Olsson, AstraZeneca R&D Lund on behalf of IPAC-RS DDU Working Group
More informationUse of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung
Use of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung Nia Stevens 9 th November 2016 Thanks to Richard Kaye, James Mitchell, Dave Prime at GSK Bahman Asgharian and Owen
More informationOVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA)
OVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA) Terrence P. Tougas on behalf of the IPAC-RS Cascade Impactor Working Group IPAC-RS 2011 Conference 1 CI WG Members 1. Steve Stein 3M 2. Mårten Svenson AstraZeneca
More informationBiopharmaceutics of Non-Orally Administrated Drugs
Biopharmaceutics of Non-Orally Administrated Drugs Robert Lionberger, Ph.D. Deputy Director for Science (acting) Office of Generic Drugs, FDA November 21, 2013 AAPS Webinar Opinions expressed in this presentation
More informationRespiratory. Martin Jetzer DDL27 Edinburgh December 2016
Respiratory Investigating the Effect of the Force Control Agent Magnesium Stearate in Fluticasone Propionate Dry Powder Inhaled Formulations with Single Particle Aerosol Mass Spectrometry Martin Jetzer
More information21/03/2011 AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY. Fundamentals of aerosols
AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY AEROSOL DEPOSITION AND THE ASSESSMENT OF PULMONARY DRUG DELIVERY Steve Newman Scientific Consultant Norfolk, UK steve.newman@physics.org
More informationGeneric Inhaled Medications
Generic Inhaled Medications Financial Interest Disclosure (over the past 24 months) Irvin Mayers Company Speaker Advisory Research Medimmune Novartis GSK Boehringer Ingelheim CADTH Health Canada Financial
More informationEquivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi)
Respiratory Drug Delivery Europe 2017 Nagel and Suggett Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi) Mark W. Nagel and Jason A. Suggett
More informationCase Study 1: Pharmaceutical Development of EXUBERA
Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human
More informationNonclinical Safety Evaluation of Inhalation Drug Products
Nonclinical Safety Evaluation of Inhalation Drug Products February 13, 2002 Life Science Research Organization Bethesda, Maryland Luqi Pei, Ph.D. Division of Pulmonary and Allergy Drug Products Center
More informationCOPLEY SCIENTIFIC. Quality Solutions for Inhaler Testing. metered-dose inhalers dry powder inhalers nebulisers nasal sprays
COPLEY SCIENTIFIC Quality Solutions for Inhaler Testing 2015 Edition metered-dose inhalers dry powder inhalers nebulisers nasal sprays Who are Copley Scientific? Copley Scientific was founded in 1946 in
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationIMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING
IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING In this piece, Mark Copley, Sales Director of Copley Scientific, provides some background on mouth-throat models for
More informationThe Role of EPAG in Standards and Regulatory Guidance Development
The Role of EPAG in Standards and Regulatory Guidance Development Jolyon P. Mitchell on behalf of EPAG Session 4: The Remit, Activities and Achievements of The European Pharmaceutical Aerosols Group 1
More informationCOMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES
COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation
More informationFirst to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction
More informationCOPLEY SCIENTIFIC. Quality Solutions for Inhaler Testing Edition. metered-dose inhalers dry powder inhalers nebulisers nasal sprays
COPLEY SCIENTIFIC Quality Solutions for Inhaler Testing 2012 Edition metered-dose inhalers dry powder inhalers nebulisers nasal sprays Who are Copley Based in Nottingham, UK, Copley Scientific was founded
More informationBest Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables
Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group PQRI Training Course 12-13 April 2007 Chicago, IL What are leachables
More informationLessons Learned from Approval of Generic Nasal Products
Lessons Learned from Approval of Generic Nasal Products Julie D. Suman, Ph.D President, Next Breath IPAC-RS/UF Orlando Inhalation Conference: Approaches in International Regulation March 20, 2014 Objectives
More informationCAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing
More informationTechnology and Quality of Inhalation Drug Products
Technology and Quality of Inhalation Drug Products Good Development Practices, Specifications, and Analytical Methods for Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Respiratory Drugs 5 6 November
More informationPublic Assessment Report Scientific discussion. Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC
Public Assessment Report Scientific discussion Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC This module reflects the scientific discussion for the approval
More informationOPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER
OPTIMISING ANALYTICAL STRATEGIES FOR THE DEMONSTRATION OF BIOEQUIVALENCE IN A GENERIC NEBULISER US FDA guidance for the in vitro demonstration of bioequivalence in a generic nebuliser directly references
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationQuality of Nasal and Inhalation Drug Products
Quality of Nasal and Inhalation Drug Products Good Development Practices, Specifications, and Analytical Methods for Inhalation Drug Products (Metered Dose Inhaler (MDI), Dry Powder Inhaler (DPI)) and
More informationUniversity of Groningen. Technology in practice Lexmond, Anne
University of Groningen Technology in practice Lexmond, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationRDD Europe 2009 Workshop
RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution. An Introduction to Differentiating
More informationCharacterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing
INSTRUMENTATION» Characterizing the Performance of Metered Dose Inhalers with Add-On Devices: New Methods For Clinically Relevant Testing Mark Copley Director Copley Scientific The recent introduction
More informationBrief Overview of the PQRI Recommendations: Challenges and Successes
Brief Overview of the PQRI Recommendations: Challenges and Successes Daniel L. Norwood, MSPH, PhD Distinguished Research Fellow Boehringer Ingelheim Pharmaceuticals, Inc. Available FDA Guidances Container
More informationMisty Max 10 nebulizer
AirLife brand Misty Max 10 nebulizer Purpose Introduction Delivery of nebulized medication to the lungs is a complex process dependant upon a variety of clinical and device-related variables. Patient breathing
More informationDrug/Device Combination Products: Bioequivalence
Drug/Device Combination Products: Bioequivalence Three stories:. The story of Nasal and Inhalation Product BE 2. The story of the Generic Auto-Injector 3. The story of User Interface Considerations Bioequivalence
More informationYour Inhaler Devices & You
1 Your Inhaler Devices & You COUNSEL ON THE APPROPRIATE USE OF A: METERED DOSE INHALER (MDI) DRY POWDER INHALER (DPI) DISCUSS THE APPROPRIATE USAGE OF A PEAK FLOW METER AND SPACER/HOLDING CHAMBER DEVICE
More informationInhalation Therapy. Inhalation Therapy
Matching Device and Patient Matching Patient to the Device Søren Pedersen University of Southern Denmark Kolding Hospital Anatomical factors (age) Training and education Delivered dose Psycomotor skills
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Poonam Sheth, PharmD, PhD, Research Scientist, Inhalation Matthew T. Marmura, Research Scientist, Inhalation Recipharm is frequently asked to help
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationSELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS. Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical
SELECTING A DOSAGE FORM FOR DRUG DELIVERY TO THE LUNGS Dr. Jay T. Holt, Ph.D., Sr. Director, Inhalation & Analytical www.cirruspharm.com February 2014 INTRODUCTION Cirrus, a Kemwell company, is frequently
More informationUPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
UPDATE ON THE GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS DDL2017 6-8 December 2017 Presented by Claudia Vincenzi on 7 December 2017 Quality Office EMA An agency of the European
More informationDISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs
Issue: March 2016, Posted Date: 3/1/2016 DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs INTRODUCTION In the development of orally inhaled and nasal products
More informationRespiratory Therapy. Medical/Scientific/General Background
Respiratory Therapy Medical/Scientific/General Background Marketing Europe Dr. Rainer Jakobs PMM Europe 1 Dr. Rainer Jakobs, PMM Europe RT Medical/Scientific/General Background 2 Dr. Rainer Jakobs, PMM
More informationMetered Dose Inhalation Formulations of Salbutamol Sulphate Using Non-CFC Propellant Tetrafluoroethane
Available online at www.ijpsdr.com International Journal of Pharmaceutical Sciences and Drug Research 2011; 3(4): 292-296 Research Article ISSN 0975-248X Metered Dose Inhalation Formulations of Salbutamol
More informationNational Transition Strategy to Replace CFC-based. MDIs with in the Commonwealth of Independent States. Paul Krajnik UNIDO, Montreal Protocol Branch
National Transition Strategy to Replace CFC-based MDIs with HFA-MDIs in the Commonwealth of Independent States Paul Krajnik UNIDO, Montreal Protocol Branch 1 Starting point: total CFC phase-out CFC phase-out
More informationPredictive modeling of deposition, dissolution, absorption and systemic exposure
Predictive modeling of deposition, dissolution, absorption and systemic exposure IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Per Bäckman and Bo Olsson, AstraZeneca R&D, Mölndal Sweden The views
More informationDemonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products
Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products Extended Breakout Session 2: Biomarker Strategies Richard C. Ahrens, M.D. Partha Roy, Ph.D. Dale P. Conner, Pharm.D. Regulatory
More informationFormulation Considerations for Inhaled Products
Formulation Considerations for Inhaled Products Formulation Considerations of Inhaled Products Inhalation Therapy Nebulizers and Formulations Dry Powder Inhalers and Formulations Metered Dose Inhalers
More informationOptimising the application of in vitro test methods for the demonstration of bioequivalence in orally inhaled products
Optimising the application of in vitro test methods for the demonstration of bioequivalence in orally inhaled products Mark Copley, Director and Anna Sipitanou, Business Development Manager, Copley Scientific
More informationA Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data
A Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data IPAC-RS/UF Orlando Inhalation Conference March 18-20, 2014 Dennis Sandell, S5 Consulting Contents The data brief
More informationA NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING
A NEW, ADVANCED HIGH- THROUGHPUT SYSTEM FOR AUTOMATED INHALER TESTING Two years ago, Novi Systems Ltd set out to shake up the inhaler automation market. On December 8th, 2015, at the Drug Delivery to the
More informationFORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels
Seite 1 von 8 Share this story: Issue: April 2015, Posted Date: 3/30/2015 FORMULATION DEVELOPMENT - A QbD Approach to Develop Extended Release Softgels INTRODUCTION Soft gelatin capsules (softgels) continue
More informationOrganic Impurities in Drug Substances and Drug Products. Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017
Organic Impurities in Drug Substances and Drug Products Antonio Hernandez-Cardoso, M.Sc. Senior Scientific Liaison September 8, 2017 Potential sources of drug impurities during development AAPS PharmSciTech,
More informationAdvance in inhaler technique: changes in delivery devices, Authorized Generics, and Advance in technology for monitoring inhaler adherence
Advance in inhaler technique: changes in delivery devices, Authorized Generics, and Advance in technology for monitoring inhaler adherence Bruce Brown, MS, RRT, AE-C Nemours Healthcare System Disclosures
More informationEverything for Inhalation
Everything for Inhalation Everything for Inhalation Inhalation drug product development at Hovione has a strong focus on formulation for Dry Powder Inhalers (DPI), particularly for capsule-based and reservoir-based
More informationWhat you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG
What you need to know about inhalers and how to use them Henry Chrystyn PhD, FRPharmS and David Price MA, MRCGP, DRCOG VM The authors describe the problems that arise with metered-dose and dry-powder inhalers,
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationIPAC-RS Conference Rockville, Maryland March 31, 2011
IPAC-RS Conference Rockville, Maryland March 31, 2011 Leachables and Extractables: Evolution of Regulatory Aspects and Perspectives on PQRI Recommendations Guirag Poochikian, Ph.D. Poochikian Pharma Consulting
More informationResearch Article. *Corresponding author Mahesh M.Giri
Scholars Academic Journal of Pharmacy (SAJP) ISSN 2320-4206 Sch. Acad. J. Pharm., 2013; 2(3):260-267 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationOrally Inhaled Corticosteroids to 2022
Greystone Research Associates 1+603-595-4340 April 2015 Orally Inhaled Corticosteroids to 2022 Drugs, Devices, Markets and Forecasts Contents A Comprehensive Market Analysis Report Scope & Overview 2 Table
More informationProduct Guide. MSP Corporation Rice Creek Parkway, Suite 300. Shoreview, Minnesota 55126, U.S.A. Phone: Fax:
Product Guide inhalertesting MSP Corporation 5910 Rice Creek Parkway, Suite 300 Shoreview, Minnesota 55126, U.S.A. Phone: 651.287.8100 Fax: 651.287.8140 sales@mspcorp.com www.mspcorp.com About This Guide
More information